Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
TMCI 
Treace Medical Concepts Inc (TMCI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: TMCI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.47
1 Year Target Price $5.47
| 2 | Strong Buy |
| 0 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.67% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 174.59M USD | Price to earnings Ratio - | 1Y Target Price 5.47 |
Price to earnings Ratio - | 1Y Target Price 5.47 | ||
Volume (30-day avg) 7 | Beta 0.73 | 52 Weeks Range 2.56 - 10.79 | Updated Date 12/6/2025 |
52 Weeks Range 2.56 - 10.79 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -22.89% | Operating Margin (TTM) -29.23% |
Management Effectiveness
Return on Assets (TTM) -14.77% | Return on Equity (TTM) -51.63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 184039026 | Price to Sales(TTM) 0.8 |
Enterprise Value 184039026 | Price to Sales(TTM) 0.8 | ||
Enterprise Value to Revenue 0.84 | Enterprise Value to EBITDA -40.95 | Shares Outstanding 63718073 | Shares Floating 47408795 |
Shares Outstanding 63718073 | Shares Floating 47408795 | ||
Percent Insiders 25.36 | Percent Institutions 61.18 |
Upturn AI SWOT
Treace Medical Concepts Inc
Company Overview
History and Background
Treace Medical Concepts, Inc. was founded in 2014. It focuses on developing and commercializing orthopedic solutions for bunion correction.
Core Business Areas
- Bunion Correction Solutions: Treace develops, manufactures, and markets the Lapiplastyu00ae System, a platform designed for the correction of bunions. They also offer related instrumentation and biologics.
Leadership and Structure
The leadership team includes John T. Treace (CEO), Lee V. Senter (CFO), and other experienced executives. The company operates with a focus on innovation and commercial execution within the bunion correction market.
Top Products and Market Share
Key Offerings
- Lapiplastyu00ae System: The Lapiplastyu00ae System is Treace's flagship product, a surgical procedure for correcting bunions using a triplane correction approach. While precise market share data is not publicly available, Treace has established a significant presence in the bunion correction market. Competitors include Stryker, Wright Medical (now part of Stryker), and other companies offering bunion correction implants and procedures.
Market Dynamics
Industry Overview
The orthopedic bunion correction market is characterized by a mix of traditional and newer surgical approaches. Growth is driven by an aging population, increasing awareness of bunion treatments, and technological advancements.
Positioning
Treace Medical Concepts positions itself as a leader in bunion correction with its Lapiplastyu00ae System. Its competitive advantage lies in the unique triplane correction approach and clinical data supporting the procedure's effectiveness.
Total Addressable Market (TAM)
The total addressable market for bunion correction is estimated to be in the billions of dollars globally. Treace is positioned to capture a significant portion of this market with its innovative Lapiplastyu00ae procedure. While estimates vary, the market is robust due to the prevalence of bunions.
Upturn SWOT Analysis
Strengths
- Innovative Lapiplastyu00ae System
- Strong clinical data supporting Lapiplastyu00ae
- Focused expertise in bunion correction
- Experienced management team
Weaknesses
- Reliance on a single product (Lapiplastyu00ae)
- Smaller size compared to larger orthopedic companies
- Limited geographic reach compared to larger competitors
Opportunities
- Expanding market awareness of Lapiplastyu00ae
- Increasing adoption of Lapiplastyu00ae by surgeons
- Geographic expansion into new markets
- Potential for new product development in related areas
Threats
- Competition from established orthopedic companies
- Potential changes in reimbursement policies
- Technological advancements by competitors
- Economic downturn affecting elective surgical procedures
Competitors and Market Share
Key Competitors
- STRY
- JNJ
- BSX
Competitive Landscape
Treace's competitive advantage lies in its specialized focus and the unique technology of the Lapiplastyu00ae System. However, it faces competition from larger, more diversified orthopedic companies.
Growth Trajectory and Initiatives
Historical Growth: Treace has experienced significant revenue growth in recent years, driven by increasing adoption of the Lapiplastyu00ae System.
Future Projections: Future growth is expected to be driven by continued adoption of Lapiplastyu00ae, geographic expansion, and potential new product development. Analyst estimates vary, but generally project continued revenue growth.
Recent Initiatives: Recent initiatives include expanding the sales force, increasing marketing efforts, and investing in clinical research.
Summary
Treace Medical Concepts is a growing company with an innovative product in the bunion correction market. Its Lapiplastyu00ae System has gained traction, driving revenue growth. However, the company faces competition from larger players and relies heavily on a single product. Future success depends on continued adoption of Lapiplastyu00ae and strategic expansion.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data are estimates and may vary. Consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Treace Medical Concepts Inc
Exchange NASDAQ | Headquaters Ponte Vedra, FL, United States | ||
IPO Launch date 2021-04-23 | Founder, Chairman & CEO Mr. John T. Treace | ||
Sector Healthcare | Industry Medical Devices | Full time employees 477 | Website https://www.treace.com |
Full time employees 477 | Website https://www.treace.com | ||
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot. It serves physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.